Pharma RSS Digest - 2026-07-27
Overview
The tape is light and eclectic, with only two stories rising to the top of the window and little broader sector momentum behind them. The more substantive development is European: a positive CHMP opinion for a new oral cholesterol-lowering therapy that could reach patients still above target on existing lipid regimens. The other item is a US product-liability lawsuit tied to an infant botulism outbreak, which sits at the intersection of food safety, consumer litigation, and retail liability rather than traditional pharma pipelines. Taken together, neither story signals a sector-wide re-rating, but the CHMP opinion is the cleaner read-through for drug developers and commercial partners.
Key Developments
A Washington family has sued Nara Organics and Target over an infant botulism case linked to recalled Nara Whole Milk Organic Powdered Infant Formula, one of four infant cases across California, Pennsylvania, and Washington. The complaint names both the manufacturer and the retailer under the Washington Product Liability Act, and takes direct aim at marketing language describing the product as "FDA-approved" — a label the FDA does not actually apply to infant formula. The FDA has tied recalled lots to Organic West Milk and Dairy Farmers of America spray-drying, the same suppliers implicated in the 2025 ByHeart outbreak that sickened 48 infants across 17 states. Watch for any additional lawsuits from the other affected families, the duration of the discovery process, and whether regulators take enforcement action against either Nara or Target beyond the civil case.
NewAmsterdam Pharma and the Menarini Group received a positive CHMP opinion recommending EU marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in primary hypercholesterolemia, including heterozygous familial hypercholesterolemia. Phase III data from the BROADWAY, BROOKLYN, and TANDEM trials supported the recommendation, with reported LDL-C reductions of up to 40% on monotherapy and around 50% on the combination versus placebo, and a tolerability profile described as placebo-like. The opinion is non-binding and now goes to the European Commission, with a final decision expected in the second half of 2026; Menarini holds exclusive European commercialization rights while NewAmsterdam is positioned for tiered double-digit royalties of up to roughly 25% and up to €833 million in milestones. Watch the EC decision timing, country-by-country launch sequencing, and most importantly the readout from the PREVAIL cardiovascular outcomes trial, which is likely to shape payer adoption and any future label expansion.